Study Reports High Response Rates to Metastasis-Directed Radiation Therapy in SMARCB1-Deficient RMC - Pavlos Msaouel @PavlosMsaouel oncodaily.com/science/pavlos…

Key Updates in GU Oncology From ESMO 2026 ESMO 2026 presented significant efficacy findings and updated survival results across GU oncology. Key highlights: ▫️ VOLGA: Durvalumab + EV improved EFS (HR 0.51) and OS (HR 0.58) in MIBC. ▫️ DASL-HiCaP: Darolutamide + ADT and radiotherapy improved MFS (HR 0.42). ▫️ PROTEUS substudy: Perioperative apalutamide + ADT and surgery improved EFS versus surgery alone (HR 0.38). ▫️ PEACE-1: Long-term OS benefit confirmed with abiraterone-based treatment (HR 0.75). ▫️ PE-PE (Phase II): Pembrolizumab + MDT improved RFS in oligometastatic RCC (HR 0.47). ▫️ KEYNOTE-564: Adjuvant pembrolizumab maintained DFS and OS benefits. ▫️ LITESPARK-011: PFS benefit maintained (HR 0.74); final OS was not statistically significant. Takeaway: ESMO 2026 provided new evidence for treatment intensification alongside longer-term confirmation of established benefits. @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO26 #OncoDaily

Excited to See Our ARON Research Published in Nature Communications - Francesco Massari @fmassari79 @MatteoSantoniMD @TarekTahaMD oncodaily.com/science/france…

CAPItello-281 Adds New Overall Survival Data in Metastatic Prostate Cancer - Adam B. Weiner @Adam_Weiner535 oncodaily.com/science/adam-b…

Bravo Brian Rini on Advancing Biomarker-Driven Treatment Selection in RCC - Shilpa Gupta @shilpaonc @brian_rini oncodaily.com/voices/shilpa-…

Happy to Share Our Review on Prostate Cancer Risk Factors and Prevention With Giorgio Gandaglia - Adam B. Weiner @Adam_Weiner535 @GGandaglia oncodaily.com/science/adam-b…

🚨 FDA Approved Talazoparib Plus Enzalutamide for HRR-Mutated Metastatic Castration-Sensitive Prostate Cancer On October 26, 2026, the FDA approved talazoparib plus enzalutamide for adults with HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, based on results from the Phase III TALAPRO-3 trial. Key findings: ▫️ Median rPFS: Not reached with talazoparib plus enzalutamide vs 45.8 months with placebo plus enzalutamide (HR 0.48; 95% CI 0.36–0.65; p<0.0001). ▫️ Overall survival: Data remained immature. ▫️ ESMO 2026: Arun A. Azad presented a separate TALAPRO-3 biomarker analysis (2219RO). Among patients ctDNA-positive at baseline, conversion to ctDNA-negative at Week 5 occurred in 82.1% vs 68.2% of evaluable patients, respectively. Early ctDNA changes were associated with rPFS. Takeaway: This approval expands treatment options for patients with HRR-mutated metastatic prostate cancer in the androgen pathway modulation-naïve or -sensitive setting, supported by a statistically significant rPFS benefit. Further follow-up is needed to establish the effect on overall survival. @US_FDA @oncodaily @AzadOncology @neerajaiims @quimmateo @nealshore oncodaily.com/genitourinary-… #FDA #ProstateCancer #TALAPRO3 #ESMO26

ESMO26 Highlights an International Investigator-Led Study in First-Line RCC - Elizabeth Nally @BethN01 @crisbergerot oncodaily.com/voices/elizabe…

HARMONi-GI1 Shows Improved Overall Survival With Ivonescimab in Advanced BTC - Sakditad Saowapa @SakditadMD oncodaily.com/science/sakdit…

ENZARAD Results Raise Questions About Enzalutamide With ADT and Radiotherapy - Jarad Martin @DocJarad oncodaily.com/science/jarad-…

MSK Investigates a Novel MMAE Binder to Mitigate Neuropathy in Urothelial Cancer - David Aggen oncodaily.com/voices/david-a…

Benjamin Maughan Presents PAPMET2 Findings in Papillary RCC - Karine Tawagi @DrKarineTawagi oncodaily.com/science/karine…

Phase II REPRINT: Enfortumab Vedotin Plus Pembrolizumab in Rare Renal Carcinomas At the ESMO Congress 2026, Giuseppe Procopio presented preliminary first-stage results from the Phase II REPRINT trial (NCT06302569), evaluating enfortumab vedotin plus pembrolizumab in patients with collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC). Key findings: ▫️ Study population: 13 patients enrolled; nine evaluable after central pathological review (seven CDC and two RCCU-MP). ▫️ Objective response rate: 22% (2/9), with both responses occurring in patients with SMARCB1-deficient RCCU-MP. No objective responses were observed in CDC (0/7). ▫️ Disease control rate: 55% (5/9), including two partial responses and three cases of stable disease. ▫️ Median PFS: 5.2 months (95% CI 3.4–not reached). ▫️ Safety: No Grade 3–4 adverse events were reported. ▫️ Biomarkers: Both responding tumours were negative for membranous NECTIN-4 expression. Takeaway: REPRINT demonstrated preliminary antitumour activity and met the prespecified criteria to proceed beyond the first stage of Simon’s two-stage design. The findings are encouraging in the small RCCU-MP subgroup, but further evaluation is needed to establish efficacy and safety. @g_procopio_ @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO2026 #REPRINT #RenalMedullaryCarcinoma

Ivonescimab Shows Promising Activity in IMDC Good-Risk Renal Cell Carcinoma - Tom Powles @tompowles1 oncodaily.com/science/tom-po…

ESMO26 Showcases VOLGA Trial Findings Published in NEJM - Lazar Popovic @LazarPo31787807 oncodaily.com/voices/lazar-p…

ESMO26 Highlights JNJ-6143’s First-in-Class Approach to Targeting Prostate Cancer - Mark Wildgust @MAWildgust oncodaily.com/science/mark-w…

Phase III LITESPARK-011: Health-Related Quality of Life and Clinical Outcomes in Advanced RCC At ESMO Congress 2026, Daniel Heng presented a post hoc analysis of LITESPARK-011 (3595RO), examining associations between health-related quality of life (HRQoL), progression-free survival (PFS), and overall survival (OS) in patients with advanced clear cell renal cell carcinoma following anti–PD-(L)1 therapy. Key findings: ▫️ 741 patients were included in the exploratory analysis. ▫️ Baseline HRQoL: Higher FKSI-DRS scores were associated with more favourable PFS (HR 0.86; 95% CI 0.81–0.91) and OS (HR 0.81; 95% CI 0.77–0.86). ▫️ Longitudinal HRQoL: Higher FKSI-DRS scores over time were associated with more favourable PFS (HR 0.82; 95% CI 0.76–0.89) and OS (HR 0.57; 95% CI 0.52–0.62). ▫️ Landmark analyses: OS hazard-ratio estimates generally favoured stable or improved HRQoL at Weeks 13, 25, and 53, while PFS associations were less consistent. Takeaway: Higher baseline HRQoL scores and favourable HRQoL changes during treatment were generally associated with better clinical outcomes, particularly OS. These exploratory findings demonstrate associations and do not establish causation. @DrDanielHeng @motzermd @AndreaNecchi oncodaily.com/genitourinary-… #ESMO2026 #LITESPARK011 #RCC

RAMPART: Quality-of-Life Outcomes With Adjuvant Durvalumab in Resected RCC At ESMO Congress 2026, Sophie Merrick presented patient-reported outcomes from the RAMPART trial (3590RO), comparing adjuvant durvalumab with active monitoring in 218 patients with resected renal cell carcinoma. Key findings: ▫️ Primary QoL endpoint: No evidence of a difference in overall health and quality of life (OHQL) between groups at Month 15. ▫️ Week 16: Durvalumab was associated with clinically meaningful worsening in OHQL (−7.4), role functioning (−7.1), cognitive functioning (−5.3), fatigue (+5.5), and appetite loss (+5.8). ▫️ Month 15: Differences persisted in cognitive functioning (−7.1) and appetite loss (+7.4), with later worsening in dyspnoea (+7.5) and constipation (+12.2). Takeaway: Although the primary QoL endpoint showed no evidence of a difference, exploratory domain-specific analyses identified clinically meaningful effects during and after adjuvant durvalumab treatment. These findings require cautious interpretation, particularly the single-item dyspnoea and constipation outcomes. @tompowles1 @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO2026 #RAMPART #OncoDaily

Phase III KEYNOTE-564: Final Analysis of Adjuvant Pembrolizumab in Clear Cell RCC At ESMO 2026, Toni K. Choueiri presented the final protocol-prespecified analysis of the Phase III KEYNOTE-564 trial (3589RO), evaluating adjuvant pembrolizumab versus placebo in 994 patients with ccRCC at increased risk of recurrence following surgery. Key findings: ▫️ Median follow-up: 85.9 months. ▫️ 7-year DFS: 57.2% vs 44.6% (HR 0.68; 95% CI 0.56–0.82). ▫️ 7-year OS: 82.3% vs 76.6% (HR 0.70; 95% CI 0.53–0.92). ▫️ Subgroup analyses: DFS and OS findings remained consistent with earlier reports across key risk groups and sarcomatoid features. ▫️ Safety: No new safety signals or serious treatment-related adverse events were reported. Takeaway: After approximately seven years of follow-up, adjuvant pembrolizumab maintained its previously established DFS and OS benefits, reinforcing its role as a standard of care for patients with ccRCC at increased risk of recurrence after nephrectomy. @DrChoueiri @tompowles1 @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO2026 #KEYNOTE564

Phase III LITESPARK-011: Final Analysis of Belzutifan Plus Lenvatinib in Advanced RCC At ESMO 2026, Daniel Y. Heng presented the final analysis of LITESPARK-011 (3587O), evaluating belzutifan plus lenvatinib versus cabozantinib in advanced clear cell RCC following anti–PD-(L)1 therapy. Key findings: ▫️ Median PFS: 14.8 vs 10.8 months (HR 0.74; 95% CI 0.62–0.88). ▫️ ORR: 53.1% vs 40.2%. ▫️ Median OS: 33.7 vs 28.6 months (HR 0.85; 95% CI 0.70–1.03); the prespecified statistical significance threshold was not met. ▫️ Grade ≥3 TEAEs: 85.4% vs 83.0%. Takeaway: Belzutifan plus lenvatinib maintained the previously established PFS and ORR benefits over cabozantinib, while the final OS analysis did not demonstrate a statistically significant improvement. @motzermd @DrIacovelli @AndreaNecchi @oncodaily @myESMO oncodaily.com/genitourinary-… #ESMO26 #LITESPARK011 #RCC #OncoDaily